NP202
/ Armaron Bio
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
September 08, 2025
Ca2+/Calmodulin-Dependent Protein Kinase II (CaMKII)-Targeted Drug Discovery: Challenges and Strategies.
(PubMed, Ageing Res Rev)
- "Current CaMKII inhibitors can be classified into the following categories: CaM-binding site blockers (KN62, KN93); ATP-competitive inhibitors (AS105, GS-680, RA306, RA608, SMP-114, NP202, hesperadin); substrate-binding site blockers (AIP, AC3-I, CN21); and pathway-targeted novel modulators (e.g., Athycaltide-1)...Several innovative approaches hold promise for overcoming current limitations, including: activating endogenous degradation of CaMKII by proteolysis-targeting chimeras (PROTACs), applying novel materials such as peptide- or nucleic acid-based agents and CRISPR-Cas9-mediated gene editing approaches, employing tissue-specific delivery systems and engineered drug molecules, and targeting disease-specific signaling pathways. Together, these strategies may pave the way for more precise and effective CaMKII-targeted interventions in aging-associated diseases."
Journal • Review • Targeted Protein Degradation
December 14, 2021
NP202 treatment improves left ventricular systolic function and attenuates pathological remodelling following chronic myocardial infarction.
(PubMed, Life Sci)
- "Improved LV function and structural changes observed with NP202 may be mediated through inhibition of inflammatory and apoptotic processes in the MI setting. NP202 could therefore prove a useful addition to standard therapy in patients with post-MI LV dysfunction."
Journal • Cardiovascular • Fibrosis • Immunology • Inflammation • Myocardial Infarction • CASP3 • CCL2
April 16, 2021
Calcium/Calmodulin-Dependent Protein Kinase II Delta Inhibition and Ventricular Remodeling After Myocardial Infarction: A Randomized Clinical Trial.
(PubMed, JAMA Cardiol)
- P2 | "To determine whether NP202, an orally active inhibitor of CaMKIId, prevents LV remodeling in patients after anterior STEMI with early residual LV dysfunction...The drug was safe and well tolerated. ClinicalTrials.gov Identifier: NCT02557217."
Clinical • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • CAMK2D
1 to 3
Of
3
Go to page
1